Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte (Nasdaq: PCVX) priced concurrent public offerings of common stock, pre-funded warrants and $500 million of convertible senior notes. The equity offering includes 7,412,500 shares at $64.00 each and warrants for 400,000 shares at $63.999 each, with a $0.001 exercise price. Expected gross proceeds are approximately $500 million from equity and $500 million from notes, before expenses and excluding warrant exercises and underwriter options.
The senior unsecured notes bear 1.50% annual interest, mature October 15, 2032, and initially convert at approximately $89.60 per share. Underwriters have 30-day options for up to 1,171,875 additional shares and $75 million of additional notes. Vaxcyte plans to fund VAX-31 clinical development, manufacturing capacity and inventory, adult U.S. launch preparations and other research. The offerings are independent and expected to close October 9, 2026, subject to customary closing conditions.
Vaxcyte (Nasdaq: PCVX) has commenced separate proposed public offerings of common stock and pre-funded warrants, and convertible senior notes. The equity offering is $500 million; the notes comprise $500 million in principal. Vaxcyte intends to grant a 30-day option for up to $75 million of additional common stock and expects a 30-day option for up to $75 million of additional notes solely to cover over-allotments.
The senior unsecured notes would mature on October 15, 2032 and pay interest semi-annually. Interest and initial conversion rates will be set at pricing. Conversions may be settled in cash, shares or both at Vaxcyte's election. Neither offering depends on the other closing. Vaxcyte plans to fund VAX-31 adult and pediatric development, manufacturing capacity and inventory, anticipated U.S. adult launch preparations, other vaccine research and general corporate purposes.
Vaxcyte (PCVX) reported that VAX-31 met all prespecified primary endpoints in OPUS-1, its pivotal adult Phase 3 pneumococcal vaccine trial. In adults 50 and older, all 28 serotypes shared with PCV20 and/or PCV21 met noninferiority criteria, testing whether immune responses were not materially worse. Three unique serotypes and cross-reactive serotype 20B met superiority criteria. All 321 comparisons in adults aged 18-49 versus those aged 50-64 met noninferiority criteria.
Individual comparisons passed the stricter threshold for 20 of 20 serotypes versus PCV20 and 17 of 19 versus PCV21; serotypes 3 and 12F passed only the historical threshold versus PCV21. Safety was similar across vaccines. Vaxcyte expects OPUS-2 and OPUS-3 results in the first half of 2027, supporting a planned license application in the first half of 2028, subject to FDA review.
Vaxcyte (PCVX) will host a webcast and conference call on October 5, 2026, to present OPUS-1 Phase 3 topline data.
The event starts at 8:00 a.m. ET / 5:00 a.m. PT. The pivotal adult trial evaluates VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, for safety, tolerability and immunogenicity, or its ability to trigger an immune response. The webcast will be available on the company’s investor relations website and archived for at least 30 days.
Vaxcyte (PCVX) appointed Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer and tightened guidance for the VAX-31 adult Phase 3 OPUS-1 topline readout to the end of October 2026.
Jodar previously served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases at Pfizer, where he helped lead clinical development and medical affairs for pneumococcal conjugate vaccines Prevnar 13 and Prevnar 20, as well as other major vaccine and antiviral programs. McAvoy most recently led a 235-person legal, compliance and government affairs organization at Teva and has prior experience steering biopharma companies through IPOs and a $2.1 billion acquisition.
The VAX-31 adult Phase 3 OPUS program includes three fully enrolled trials (OPUS-1, OPUS-2 and OPUS-3), with 6,191 adults dosed, about 3,500 of whom received VAX-31. Additional OPUS-2 and OPUS-3 data are anticipated in the first half of 2027.
Vaxcyte (Nasdaq: PCVX) announced that its management will take part in fireside chats and one-on-one meetings at two investor events: the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026, and the Cantor Global Healthcare Conference on September 9-11, 2026. Webcasts of both fireside chats will be available on Vaxcyte’s investor website for about 30 days after each conference.
Vaxcyte (Nasdaq: PCVX) reported second quarter 2026 results and pipeline progress. Cash, cash equivalents and investments totaled $2.51 billion at June 30, 2026, up from $2.44 billion at year-end 2025. R&D expenses were $267.9 million and G&A expenses were $34.9 million, leading to a quarterly net loss of $284.3 million, versus $166.6 million a year earlier.
All three adult Phase 3 OPUS trials of VAX-31 are fully enrolled with 6,191 adults dosed, and topline OPUS-1 data are expected in Q4 2026, with OPUS-2 and OPUS-3 readouts in the first half of 2027. The VAX-31 infant Phase 2 study is fully enrolled, with topline primary series and booster data expected by the end of the first half of 2027. Vaxcyte also initiated a Phase 1 study of VAX-A1 for Group A Streptococcus, with topline data planned for the second half of 2027, and appointed vaccine industry veterans Moncef Slaoui and John Markels to its board.
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine company, announced participation in two July 2026 investor conferences. Management will attend the Leerink Partners Therapeutics Forum with one-on-one meetings on July 15, and the BTIG Virtual Biotechnology Conference with one-on-one meetings on July 28.
Vaxcyte (Nasdaq: PCVX) dosed the first participant in its Phase 1, first-in-human study of VAX-A1, a prophylactic vaccine candidate against Group A Streptococcus, in healthy adults aged 18–40. The randomized, placebo-controlled trial will assess safety, tolerability and initial immune responses, with topline data expected in 2H 2027.
Vaxcyte (Nasdaq: PCVX) reported Q1 2026 results and a business update. As of March 31, 2026, cash, cash equivalents and investments totaled $2.74 billion. Enrollment is complete for three VAX-31 adult Phase 3 OPUS trials (6,191 adults dosed). OPUS-1 topline data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027. Infant Phase 2 enrollment completed (900 infants); infant readouts expected by end of H1 2027. Company plans to start a Phase 1 adult study for VAX-A1 in mid-2026. Q1 R&D expense was $312.8 million and net loss was $320.6 million.